<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter A Nigrovic, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jordan S Orange, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sheldon L Kaplan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth TePas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 03, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The best-characterized autoinflammatory diseases are relatively rare but florid conditions that arise from pathogenic variants in single genes. The prototypical autoinflammatory disorders are the periodic fever syndromes. One of these disorders, the tumor necrosis factor (TNF) receptor-1 associated periodic syndrome (TRAPS; MIM #142680, formerly known as familial Hibernian fever), is reviewed here. An overview of autoinflammatory diseases is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/5597.html" rel="external">
          "The autoinflammatory diseases: An overview"
         </a>
         .)
        </p>
        <p>
         Detailed descriptions of the clinical manifestations, diagnosis, and treatment of the major autoinflammatory diseases are presented elsewhere. Classification and genetic testing for inborn errors of immunity are also discussed in detail separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/117758.html" rel="external">
          "Inborn errors of immunity (primary immunodeficiencies): Classification"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/116805.html" rel="external">
          "Genetic testing in patients with a suspected primary immunodeficiency or autoinflammatory syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/116307.html" rel="external">
          "Autoinflammatory diseases mediated by interferon production and signaling (interferonopathies)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/122506.html" rel="external">
          "Autoinflammatory diseases mediated by inflammasomes and related IL-1 family cytokines (inflammasomopathies)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/122508.html" rel="external">
          "Autoinflammatory diseases mediated by NFkB and/or aberrant TNF activity"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/122509.html" rel="external">
          "Autoinflammatory diseases mediated by miscellaneous mechanisms"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/132472.html" rel="external">
          "Deficiency of adenosine deaminase 2 (DADA2)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5585.html" rel="external">
          "Cryopyrin-associated periodic syndromes and related disorders"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2634.html" rel="external">
          "Familial Mediterranean fever: Epidemiology, genetics, and pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2635.html" rel="external">
          "Clinical manifestations and diagnosis of familial Mediterranean fever"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2574.html" rel="external">
          "Management of familial Mediterranean fever"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5956.html" rel="external">
          "Hyperimmunoglobulin D syndrome: Pathophysiology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5954.html" rel="external">
          "Hyperimmunoglobulin D syndrome: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5955.html" rel="external">
          "Hyperimmunoglobulin D syndrome: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3015183991">
         <span class="h1">
          AUTOIMMUNE VERSUS AUTOINFLAMMATORY DISEASE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many well-known disorders of immune excess result from autoimmunity, a failure of self/nonself discrimination by T and B cells, the effector cells of the adaptive arm of the immune system. (See
         <a class="medical medical_review" href="/z/d/html/5579.html" rel="external">
          "Overview of autoimmunity"
         </a>
         .)
        </p>
        <p>
         A second category of immune-mediated disease results from inappropriate activation of antigen-independent inflammatory mechanisms. This group of disorders has been termed "autoinflammatory diseases."
        </p>
        <p>
         Autoinflammatory diseases prominently involve cells of the innate immune system as well as the mediators associated with these cells. Thus, autoinflammatory diseases are broadly considered to represent primary diseases of innate immunity, in contrast to the autoimmune diseases that result from aberrant adaptive or acquired immunity. However, this separation is far from absolute [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         TRAPS is a rare disorder, with a prevalence of approximately one per million [
         <a href="#rid2">
          2-4
         </a>
         ]. While originally described in an Irish (Hibernian) kindred, cases have since been reported in many ethnic groups. Thus, ancestry plays no role in the assessment of the likelihood that a patient has this disorder.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          GENETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         TRAPS is inherited in an autosomal dominant fashion with incomplete penetrance [
         <a href="#rid4">
          4
         </a>
         ]. The genetic defect in TRAPS resides in the gene that encodes the 55 kDa receptor for TNF, TNFR1 (TNF receptor superfamily member 1A [
         <em>
          TNFRSF1A
         </em>
         gene]; MIM *191190) [
         <a href="#rid2">
          2
         </a>
         ]. In some cases, the pathogenic variants result in impaired shedding of this receptor. Some
         <em>
          TNFRSF1A
         </em>
         variants have high penetrance (ie, most persons with the variant develop the disease), while others have appreciable prevalence in healthy individuals. As an example, the arginine-to-glutamine missense mutation at amino acid 92 (R92Q mutation) is found in 2 percent of the White population, making it unlikely to be causative in isolation, but is nevertheless common among patients with a TRAPS-like illness that is usually milder and without amyloidosis [
         <a href="#rid4">
          4-6
         </a>
         ]. The P46L and T61I are common variants, particularly in Northern/Western Africa and in Japan, respectively, but may occasionally be associated with TRAPS symptomatology [
         <a href="#rid4">
          4,7,8
         </a>
         ].
        </p>
        <p>
         There is no exact correlation between genetic variant and clinical phenotype. However, the risk of secondary (inflammatory or amyloid A [AA]) amyloidosis is largely restricted to patients bearing pathogenic and likely pathogenic variants affecting certain cysteine residues. Classic presentation of intermittent fevers, rash, and abdominal pain as well as response to interleukin (IL) 1 blockade is also most common in this group [
         <a href="#rid9">
          9
         </a>
         ]. For patients with variants of unknown significance or other variants, fulfilment of Eurofever criteria for TRAPS in the absence of a confirmatory variant (at least two of the following: duration of episodes ≥7 days, myalgia, migratory rash, periorbital edema) predicted better therapeutic response to IL-1 blockade [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4024871552">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of human TRAPS remains uncertain [
         <a href="#rid10">
          10
         </a>
         ]. Impaired shedding of TNFR1 eliminates an endogenous antagonist to circulating TNF. However, other mechanisms are probably more important since patients may have normal levels of soluble TNF receptor. An excess of retained surface TNFR1 may result in enhanced susceptibility to TNF [
         <a href="#rid2">
          2,11
         </a>
         ]. Conversely, mutant receptor may bind TNF less efficiently, leading to impaired TNF-driven apoptosis [
         <a href="#rid12">
          12,13
         </a>
         ]. Finally, mutant TNFR1 may misfold and/or traffic aberrantly within the cell [
         <a href="#rid14">
          14-17
         </a>
         ]. These events can trigger an unfolded protein response (UPR; a cellular stress response associated with accumulation of unfolded or misfolded protein in the endoplasmic reticulum) or initiate TNF-independent signaling within the cell mediated by enhanced production of mitochondrial-derived reactive oxygen species that disturb intracellular signaling pathways. Thus, despite beginning with a defect in the TNF system, TRAPS appears to be mediated by other proinflammatory mediators as well, including interleukin (IL) 1 beta [
         <a href="#rid14">
          14,18
         </a>
         ]. The resulting pivotal role of IL-1 beta is evident in the success of clinical antagonism of this cytokine [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3147843693">
         <span class="h2">
          Age at presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients present in the first decade of life (median 4.3 years in the largest series of 158 patients), but approximately 10 percent present over the age of 30 years [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Fever
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recurrent fevers &gt;38°C/100.4°F over months or years in the absence of associated viral or bacterial infections are characteristic of TRAPS, occurring in at least 88 percent of patients [
         <a href="#rid3">
          3,4,8,20
         </a>
         ]. Febrile episodes every five to six weeks are typical, though clockwork periodicity is lacking. Precipitating factors are generally not identified, though some patients or caregivers observe that physical and emotional stress may tend to trigger attacks. Fever and associated symptoms commonly last at least five days and often continue for more than two weeks.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Other features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other clinical features include [
         <a href="#rid3">
          3,4,8,9,20
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myalgia and limb pain, sometimes migratory (59 to 85 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abdominal symptoms (36 to 74 percent), including pain and vomiting (18 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rash (55 to 63 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphadenopathy (25 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Headache (20 to 25 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest pain (14 to 25 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Conjunctivitis (18 to 22 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Periorbital edema (9 to 20 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pharyngitis, with or without aphthae (9 to 18 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monoarticular arthritis (13 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatomegaly and/or splenomegaly (5 to 10 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Impaired fertility and/or recurrent miscarriages (3 percent)
        </p>
        <p>
        </p>
        <p>
         Characteristically, the rash presents as single or multiple erythematous patches  (
         <a class="graphic graphic_picture graphicRef118539" href="/z/d/graphic/118539.html" rel="external">
          picture 1
         </a>
         ) that may spread distally down an extremity over time [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         Presentation as recurrent pericarditis has also been reported [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4098026124">
         <span class="h2">
          Subacute presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         A subacute presentation, reported in some adult patients, is characterized by myalgias, fatigue, and persistent elevation of inflammatory markers [
         <a href="#rid4">
          4,23
         </a>
         ]. Common variants with incomplete penetrance (eg, R92Q) may be overrepresented in this group, rendering it especially important to confirm systemic inflammation to avoid confusion with fibromyalgia and other causes of chronic pain and fatigue. (See
         <a class="medical medical_review" href="/z/d/html/5624.html" rel="external">
          "Clinical manifestations and diagnosis of fibromyalgia in adults", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Secondary (AA) amyloidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 10 to 15 percent of patients develop clinical manifestations of secondary amyloidosis, also called AA amyloidosis since the deposited protein is serum amyloid A [
         <a href="#rid3">
          3,4,24-28
         </a>
         ]. AA amyloidosis may be diagnosed first, with TRAPS identified subsequently [
         <a href="#rid29">
          29
         </a>
         ]. This form of amyloidosis primarily involves the kidney and is a potentially life-threatening complication of TRAPS. However, the liver, thyroid, heart, and other organs may be affected. The signs and symptoms of amyloidosis with TRAPS are similar to those observed with secondary amyloidosis in other disorders. Proteinuria or signs/symptoms of nephrotic syndrome suggest amyloidosis. Other suggestive clinical and laboratory features include hepatomegaly, waxy skin and easy bruising, enlarged muscles, heart failure and cardiac conduction abnormalities, peripheral and/or autonomic neuropathy, and impaired coagulation. (See
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Clinical manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3120.html" rel="external">
          "Renal amyloidosis"
         </a>
         .)
        </p>
        <p>
         The risk of secondary (AA) amyloidosis is increased among patients with pathogenic variants affecting cysteine residues (eg, C33Y), probably reflecting the higher cumulative inflammatory burden associated with these variants [
         <a href="#rid4">
          4,24
         </a>
         ]. These cysteines form intramolecular disulfide bonds that help to maintain the three-dimensional structure of TNFR1. Since 15 to 24 percent of patients with cysteine variants, or with the variant T50M, develop amyloidosis compared with only 2 to 7 percent of patients with other variants [
         <a href="#rid3">
          3,4,24
         </a>
         ], the identification of an individual patient's variant may drive therapeutic decisions. In particular, the risk of amyloidosis in patients with R92Q appears to be very low (0 of 54 in one series) [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="local">
          'Management'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          LABORATORY FINDINGS
         </span>
        </p>
        <p class="headingAnchor" id="H1979187250">
         <span class="h2">
          Inflammatory markers and autoantibodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory investigation reveals elevation of inflammatory markers including the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). Such markers are particularly elevated during attacks but commonly remain modestly elevated even during asymptomatic periods. Autoantibodies, such as rheumatoid factor and antinuclear antibodies (ANA), are usually absent or are present at low titer [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3659944074">
         <span class="h2">
          Findings associated with secondary amyloidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with involvement of the kidney and other organs with secondary amyloidosis may have proteinuria, kidney insufficiency, and dysfunction of involved organs. This is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Histology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Biopsy of involved skin reveals superficial and deep infiltration by lymphocytes and monocytes [
         <a href="#rid21">
          21
         </a>
         ]. A monocytic fasciitis, rather than a true myositis, appears to be responsible for myalgia. Serum levels of muscle enzymes are normal [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         In patients with secondary amyloidosis, the serum amyloid A protein deposits appear as amorphous hyaline material on light microscopy. (See
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Selection of biopsy site'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A diagnosis of TRAPS should be entertained only after bacterial and other infectious and neoplastic causes of recurrent fever have been excluded (see
         <a class="local">
          'Differential diagnosis'
         </a>
         below). The evaluation then proceeds with an attempt to identify a clinical pattern consistent with one of the major autoinflammatory disorders. Validated criteria have been developed for the classification of the major periodic fever syndromes  (
         <a class="graphic graphic_table graphicRef101819" href="/z/d/graphic/101819.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid30">
          30
         </a>
         ]. The diagnosis of TRAPS is suggested by a history of recurrent fever and one or more of the other clinical features noted above. There are no specific laboratory tests, outside of genetic testing, that can establish the diagnosis.
        </p>
        <p>
         Particular hallmarks of TRAPS include the protracted duration of attacks (at least six days, though typically longer), prominent myalgias, migratory rash, and periorbital edema [
         <a href="#rid3">
          3,30
         </a>
         ]. Family history is commonly positive, although some carriers of TRAPS variants may be entirely asymptomatic.
        </p>
        <p>
         The diagnosis of TRAPS is confirmed by genetic testing for disease-associated pathogenic variants in the TNFR1 gene (
         <em>
          TNFRSF1A
         </em>
         ). Testing is available commercially. A list of
         <em>
          TNFRSF1A
         </em>
         mutations is available in published references [
         <a href="#rid9">
          9
         </a>
         ] and in the online
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Finfevers.umai-montpellier.fr%2Fweb%2F&amp;token=hBdCcrJFxjzOIUX%2BBbE%2FwjWlKtb%2FeP6Zz9tp1yb3I%2BW5PxXs5L28sNptJjDJCUXSLuv1cA30YJsH2UD4hL0WpQ%3D%3D&amp;TOPIC_ID=5580" target="_blank">
          Infevers database
         </a>
         . Variants are classified as pathogenic, likely pathogenic, of unknown significance, not classified, likely benign, and benign. While R92Q (also called R121Q) is believed to represent a truly causative variant in some patients, it is sufficiently common in the healthy population that other possibilities in the differential diagnosis should still be excluded before making a final diagnosis. Some experts regard the R92Q syndrome as sufficiently different from that resulting from other
         <em>
          TNFRSF1A
         </em>
         mutations that they consider symptomatic patients bearing this variant to have a disease distinct from TRAPS [
         <a href="#rid6">
          6,23,31
         </a>
         ]. Somatic mosaicism resulting in symptomatic disease has been reported [
         <a href="#rid32">
          32,33
         </a>
         ]. (See
         <a class="local">
          'Genetics'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of recurrent fever is broad, including autoimmune diseases, other autoinflammatory diseases, and several other disorders.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Recurrent fevers due to bacterial and other infectious and neoplastic causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         As previously mentioned, a diagnosis of TRAPS should be entertained only after bacterial and other infectious and neoplastic causes of recurrent fever have been excluded. (See appropriate topic reviews.)
        </p>
        <p>
         In addition, patients with TRAPS and other periodic fevers are often evaluated initially for fever of unknown origin (FUO). General approaches to the child and to the adult with FUO are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/5993.html" rel="external">
          "Fever of unknown origin in children: Evaluation", section on 'Overview of evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5993.html" rel="external">
          "Fever of unknown origin in children: Evaluation", section on 'Initial evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2736.html" rel="external">
          "Fever of unknown origin in adults: Evaluation and management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Other immune-mediated diseases
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic lupus erythematosus (SLE) and Still's disease in children (systemic juvenile idiopathic arthritis) and adults (adult-onset Still's disease) can also present with fever, joint pain, and skin rash. Unlike TRAPS, patients with SLE almost invariably have antinuclear antibodies (ANA) and often have hypocomplementemia, glomerulonephritis, and cytopenias, which are not seen with TRAPS. Inflammatory bowel disease and vasculitis can present with fever and prominent systemic inflammation. None of these conditions typically present with stereotyped episodes of recurrent inflammation over the course of months or years. (See
         <a class="medical medical_review" href="/z/d/html/6420.html" rel="external">
          "Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">
          "Clinical manifestations and diagnosis of systemic lupus erythematosus in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Other autoinflammatory diseases
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain clinical features help to distinguish TRAPS from other autoinflammatory disorders, a family of diseases that is steadily expanding as additional members are described [
         <a href="#rid1">
          1,34
         </a>
         ]. The duration of fever is a particularly useful discriminant since none of the other defined syndromes exhibit such prolonged episodes [
         <a href="#rid35">
          35
         </a>
         ]. Other features particularly suggestive of TRAPS include myalgias, periorbital edema, and migratory rash [
         <a href="#rid30">
          30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5597.html" rel="external">
          "The autoinflammatory diseases: An overview"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Familial Mediterranean fever
         </span>
         <span class="headingEndMark">
          —
         </span>
         Familial Mediterranean fever (FMF) is a disorder characterized by episodic attacks of fever lasting one to three days and accompanied in most cases by abdominal pain, pleurisy, and arthralgias/arthritis secondary to serositis and synovitis. The diagnosis of FMF may be strongly suggested by patient ethnicity since this autoinflammatory disease is most commonly seen in certain ethnic groups including Sephardic Jews, Armenians, North Africans, and Turks and, to a lesser extent, Ashkenazi Jews, Greeks, and Italians [
         <a href="#rid30">
          30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2635.html" rel="external">
          "Clinical manifestations and diagnosis of familial Mediterranean fever"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Hyperimmunoglobulin D syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hyperimmunoglobulin D syndrome (HIDS) is an autosomal recessive periodic fever syndrome most prevalent among patients of Dutch and French origin. Episodic attacks of fever lasting three to seven days are accompanied in most cases by chills, cervical lymphadenopathy, abdominal pain, vomiting, and/or diarrhea. Other symptoms include headache, arthralgias/arthritis, aphthous ulceration, a pleomorphic rash, and, occasionally, splenomegaly. Elevated levels of immunoglobulin D (IgD; &gt;100 international units/mL) are often present, a finding that is not typical of TRAPS. Genetic testing is used to confirm the diagnosis of HIDS. (See
         <a class="medical medical_review" href="/z/d/html/5954.html" rel="external">
          "Hyperimmunoglobulin D syndrome: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          PFAPA syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         <strong>
          P
         </strong>
         eriodic
         <strong>
          f
         </strong>
         ever with
         <strong>
          a
         </strong>
         phthous stomatitis,
         <strong>
          p
         </strong>
         haryngitis, and
         <strong>
          a
         </strong>
         denitis (PFAPA) is a syndrome for which the underlying etiology and pathogenesis are uncertain. Febrile episodes of abrupt onset last three to six days and are typically, although not invariably, accompanied by one or more of the following: pharyngitis (exudative or nonexudative), mild aphthous ulcerations, and lymphadenopathy. Recurrences of fever generally occur with nearly clockwork regularity, and laboratory markers of inflammation return to normal between episodes. There are no confirmatory laboratory tests for PFAPA, but the ability to "abort" an attack with a dose or two of systemic glucocorticoids is highly suggestive of the diagnosis. Many patients in series of "TRAPS" but lacking pathogenic or likely pathogenic variants in
         <em>
          TNFRSF1A
         </em>
         had a presentation consistent with PFAPA [
         <a href="#rid9">
          9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5953.html" rel="external">
          "Periodic fever with aphthous stomatitis, pharyngitis, and adenitis (PFAPA syndrome)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          Cyclic neutropenia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cyclic neutropenia may occur in both children and adults. It is characterized by periods of severe neutropenia that recur every 14 to 35 days, although nearly all patients exhibit a cycle period of 21 days. When neutropenic, patients are prone to malaise, fever, aphthous stomatitis, and, occasionally, serious infections. Cyclic neutropenia is suggested by documented neutropenia with an absolute neutrophil count below 500/microL on at least three to five consecutive days per cycle of each of three regularly spaced cycles. Neutropenia is not observed in TRAPS. Frequent monitoring of blood counts is necessary to observe the nadir. (See
         <a class="medical medical_review" href="/z/d/html/8370.html" rel="external">
          "Cyclic neutropenia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H457771902">
         <span class="h3">
          Interferonopathies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Interferonopathies are inflammatory diseases associated with excessive interferon signaling, typically of type I interferons [
         <a href="#rid36">
          36
         </a>
         ]. Pathogenically, these disorders derive from variants that drive excessive interferon production or aberrantly amplify interferon signaling. The clinical spectrum and severity of these disorders are highly variable, but common features include persistent systemic inflammation, vasculopathic skin rashes ranging from chilblains to necrosis of acral tissues such as the nose and earlobes, pulmonary inflammation and fibrosis, lupus-like autoantibody production and resulting pathology, and, in some cases, brain inflammation with calcifications reminiscent of congenital viral infections (pseudo-TORCH syndrome) [
         <a href="#rid36">
          36,37
         </a>
         ]. Fever can occur but is not typically a dominant feature, as it is in TRAPS. Assessment of peripheral blood gene expression data for an interferon signature, available as a research test, can facilitate the diagnosis of these rare conditions [
         <a href="#rid38">
          38
         </a>
         ], but many related genes are also characterized in commercial panels testing genes associated with autoinflammation. (See
         <a class="medical medical_review" href="/z/d/html/116307.html" rel="external">
          "Autoinflammatory diseases mediated by interferon production and signaling (interferonopathies)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          SCREENING ASYMPTOMATIC RELATIVES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Whether asymptomatic relatives of an affected individual should undergo genetic testing is uncertain. Amyloidosis may develop in the absence of febrile episodes, and some authors have suggested that genetic analysis and counseling be provided to asymptomatic family members [
         <a href="#rid25">
          25
         </a>
         ]. However, the interpretation of genetic findings is complex, in particular for low-penetrance variants such as R92Q, P46L, and T61I. Accordingly, genetic screening of asymptomatic relatives is typically not recommended [
         <a href="#rid39">
          39
         </a>
         ]. In families where the risk of amyloidosis appears particularly high, testing is an option after appropriate genetic counseling. If a variant is detected, these individuals should be followed carefully and should be treated if evidence of persistent, unexplained systemic inflammation or amyloidosis-related organ dysfunction is noted. (See
         <a class="local">
          'Monitoring'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H2291468990">
         <span class="h2">
          Goals of treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goals of treatment of TRAPS are to control symptoms, prevent recurrent attacks, and reduce the risk of amyloidosis by suppressing systemic inflammation, particularly in patients bearing pathogenic or likely pathogenic cysteine variants [
         <a href="#rid23">
          23
         </a>
         ]. (See
         <a class="local">
          'Secondary (AA) amyloidosis'
         </a>
         above.)
        </p>
        <p>
         Amyloidosis in TRAPS and other periodic fever syndromes is closely associated with protracted unremitting inflammation [
         <a href="#rid27">
          27
         </a>
         ]. Normalization of inflammatory markers is believed to result in the greatest likelihood of avoiding amyloidosis, although the extent to which achieving this target is required to avoid amyloidosis or whether therapy should be escalated to attain serologic remission in a patient who is already in clinical remission remain unknown. Patients bearing the low-penetrance variants R92Q and P46L generally exhibit less severe disease and a lower amyloidosis risk than those with cysteine variants and may tolerate less intensive treatment [
         <a href="#rid28">
          28
         </a>
         ]. (See
         <a class="local">
          'Genetics'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1826078764">
         <span class="h2">
          Overview of treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         On-demand treatment only is an option for the occasional patient with rare or mild flares and who maintains normal inflammatory markers between episodes. However, most patients have more frequent attacks and ongoing inflammation even between attacks. Higher doses, longer courses, and more frequent rounds of glucocorticoids all increase the risk of glucocorticoid toxicity. In addition, ongoing inflammation increases the risk of amyloidosis. Thus, most patients are treated with ongoing therapy, typically with cytokine blockade, rather than on-demand treatment alone. Oral glucocorticoids are tapered as tolerated based upon symptoms and inflammatory markers after prophylactic therapy is started. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         and
         <a class="local">
          'Secondary (AA) amyloidosis'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3729623969">
         <span class="h2">
          On-demand treatment of attacks
         </span>
        </p>
        <p class="headingAnchor" id="H2313980208">
         <span class="h3">
          Mild attacks
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with mild flares (fever and mild discomfort easily tolerable by the patient), we suggest treatment with a nonsteroidal antiinflammatory drug (NSAID) alone  (
         <a class="graphic graphic_algorithm graphicRef142866" href="/z/d/graphic/142866.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid28">
          28,40
         </a>
         ]. Patients are typically treated with antiinflammatory doses of an NSAID, such as
         <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">
          naproxen
         </a>
         or
         <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">
          ibuprofen
         </a>
         , for three to five days. However, we suggest adding an oral glucocorticoid if symptoms increase. (See
         <a class="local">
          'Typical attacks'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h3">
          Typical attacks
         </span>
         <span class="headingEndMark">
          —
         </span>
         NSAIDs may help to control fever but are unlikely to terminate other clinical features of an attack [
         <a href="#rid28">
          28,40
         </a>
         ]. Thus, for patients with an established diagnosis of TRAPS and a typical attack (eg, fever, myalgia, migratory rash, periorbital edema, and/or abdominal pain), we suggest initial treatment of attacks with an oral glucocorticoid  (
         <a class="graphic graphic_algorithm graphicRef142866" href="/z/d/graphic/142866.html" rel="external">
          algorithm 1
         </a>
         ). This approach is based upon clinical experience in the absence of published data.
        </p>
        <p>
         A typical agent is
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         (initial dose of 1 mg/kg daily, maximum dose 60 mg/day, started at the onset of an attack followed by a gradual taper and discontinuation after 7 to 10 days). Fever and other symptoms should start to improve within the same day the glucocorticoid is started. Attacks may vary in severity. The glucocorticoid dose can be modified depending upon the degree of symptoms and the patient's own history of treatment response; for example, it may be necessary to increase prednisone or prednisolone to 1 mg/kg twice daily, or a patient may respond well to an initial dose of only 0.5 mg/kg/day.
        </p>
        <p>
         There are a few case reports of successful on-demand treatment with
         <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">
          anakinra
         </a>
         , a recombinant interleukin (IL) 1 receptor antagonist, started within 24 hours of the onset of an attack and continued for approximately one week [
         <a href="#rid41">
          41
         </a>
         ]. The benefit of this approach is that it can minimize or eliminate the need for glucocorticoids. However, it is not known whether therapy with anakinra only during attacks is sufficient to avert the risk of amyloidosis. Thus, where this option is selected, it remains essential to ensure that inflammatory markers normalize between clinical flares.
        </p>
        <p class="headingAnchor" id="H1007408234">
         <span class="h2">
          Prophylaxis
         </span>
        </p>
        <p class="headingAnchor" id="H1662584342">
         <span class="h3">
          Frequent or poorly controlled symptoms and/or risk factors for amyloidosis
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial prophylaxis
         </strong>
         – For patients with frequent attacks (arbitrarily defined and more than three to four attacks per year), inadequate response of attacks to oral glucocorticoids, persistent elevation of inflammatory markers between flares, and/or
         <em>
          TNFRSF1A
         </em>
         mutations classified as pathogenic or likely pathogenic, we suggest prophylactic therapy with
         <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">
          canakinumab
         </a>
         , a monoclonal antibody that neutralizes IL-1 beta  (
         <a class="graphic graphic_algorithm graphicRef142866" href="/z/d/graphic/142866.html" rel="external">
          algorithm 1
         </a>
         ). The use of canakinumab is based upon limited clinical trial data and clinical experience. The initial dose of canakinumab is 2 mg/kg/dose (maximum dose 150 mg) administered subcutaneously every four weeks. The dose may be repeated after seven days and subsequent doses increased to 4 mg/kg/dose (maximum dose 300 mg) if the initial response is inadequate. (See
         <a class="local">
          'Efficacy for symptom control'
         </a>
         below and
         <a class="local">
          'Efficacy for prevention of amyloidosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Refractory disease
         </strong>
         – Treatment failure is defined as inadequate symptom control (frequency and/or severity of attacks), persistent elevation of inflammatory markers (C-reactive protein [CRP] and/or serum amyloid A), or evidence of amyloidosis.
         <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">
          Anakinra
         </a>
         is an alternative for patients who do not respond to or do not tolerate
         <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">
          canakinumab
         </a>
         . For patients in whom IL-1 blockade with both canakinumab and anakinra is ineffective or poorly tolerated, we suggest treatment with
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         , a recombinant TNF receptor that inhibits TNF  (
         <a class="graphic graphic_algorithm graphicRef142866" href="/z/d/graphic/142866.html" rel="external">
          algorithm 1
         </a>
         ). Use of etanercept is supported by small observational studies, case series, and clinical experience. There are limited observational data on use of
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         , an IL-6 receptor antagonist, for patients with TRAPS. Thus, we reserve tocilizumab for patients in whom other treatment approaches have failed. (See
         <a class="local">
          'Efficacy for symptom control'
         </a>
         below and
         <a class="local">
          'Efficacy for prevention of amyloidosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Partial response to cytokine blockade
         </strong>
         – For patients with pathogenic or likely pathogenic variants who exhibit an incomplete response to cytokine blockade with
         <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">
          canakinumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">
          anakinra
         </a>
         , or
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         , we suggest adding
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         , 0.6 mg orally once to twice daily  (
         <a class="graphic graphic_algorithm graphicRef142866" href="/z/d/graphic/142866.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Efficacy for symptom control'
         </a>
         below and
         <a class="local">
          'Efficacy for prevention of amyloidosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1433856669">
         <span class="h4">
          Efficacy for symptom control
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a phase II open-label study of 20 patients with active or recurrent chronic TRAPS treated with
         <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">
          canakinumab
         </a>
         prophylaxis (dosed at 2 mg/kg subcutaneously every four weeks, maximum dose 150 mg), 95 percent experienced excellent symptom control, typically within days of initiating therapy [
         <a href="#rid42">
          42
         </a>
         ]. All patients flared off treatment, on average within 90 days of cessation of therapy, but responded with reinstitution of therapy. In a subsequent phase III trial of 46 patients with refractory TRAPS randomly assigned to canakinumab 150 mg (or 2 mg/kg if body weight ≤40 kg) subcutaneously or placebo every four weeks, a higher rate of complete resolution was seen with canakinumab than control (45 versus 6 percent, respectively) [
         <a href="#rid19">
          19
         </a>
         ]. Resolution increased to 73 percent when those receiving a second dose of canakinumab for the initial flare were included. Among patients who had a complete initial response, 83 percent remained flare free when the dosing interval was increased to every eight weeks frequency compared with 27 percent in the placebo group. A long-term follow-up of 53 patients treated with canakinumab for TRAPS demonstrated continued efficacy, although two patients developed serious infections, including one in whom therapy had to be discontinued [
         <a href="#rid43">
          43
         </a>
         ]. Canakinumab is approved by the US Food and Drug Administration (FDA) for the treatment of TRAPS [
         <a href="#rid44">
          44
         </a>
         ]. Although canakinumab is associated with an increased risk of infections in patients with other risk factors (eg, older patients with comorbidities), no specific prevention strategies are recommended for patients receiving this treatment [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         A potentially cost-effective alternative to
         <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">
          canakinumab
         </a>
         is
         <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">
          anakinra
         </a>
         , the recombinant IL-1 receptor antagonist. Unlike canakinumab, which has a half-life of approximately 24 days, anakinra is short acting, with a half-life of approximately four hours. Case reports and case series showed efficacy of anakinra 1.5 to 2 mg/kg/day (or 100 mg daily) in TRAPS, including as on-demand dosing in some patients [
         <a href="#rid40">
          40,41,46-48
         </a>
         ].
        </p>
        <p>
         In prospective case series and open-label studies, treatment with
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         , a TNF inhibitor, was associated with reduced glucocorticoid requirement or a small decrease in disease activity scores, although the response was partial in some patients and absent in others, and inflammation was not abolished [
         <a href="#rid3">
          3,49-51
         </a>
         ]. An observational study found that etanercept was helpful in 32 of 37 patients but induced complete remission in only 30 percent compared with 79 percent (26 of 33) for
         <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">
          anakinra
         </a>
         [
         <a href="#rid40">
          40
         </a>
         ]. Etanercept is initiated at typical doses of 50 mg administered subcutaneously once weekly in adults and 0.8 mg/kg (up to 50 mg) weekly in children. Paradoxically, treatment with antibodies against TNF (
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         and
         <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">
          adalimumab
         </a>
         ) is associated with flares of disease and is generally avoided [
         <a href="#rid28">
          28,52
         </a>
         ].
        </p>
        <p>
         There are a few case reports of successful treatment of patients with TRAPS with
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         [
         <a href="#rid53">
          53-55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H609247899">
         <span class="h4">
          Efficacy for prevention of amyloidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Case series, clinical experience, and extrapolation from other autoinflammatory disorders suggest that early institution of biologic therapy also lowers the risk of amyloidosis and kidney damage [
         <a href="#rid27">
          27,29
         </a>
         ], although it is unclear how long treatment is needed to prevent this complication. Historically, anti-TNF therapy (
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         ) was employed for patients with frequent and/or severe recurrences and for those with TNFR1 gene variants associated with a high risk of amyloidosis. Patients with the V173D variant (interrupting metalloproteinase cleavage of TNFR1) may respond particularly briskly to this treatment [
         <a href="#rid51">
          51
         </a>
         ]. However, the appreciation that IL-1 beta plays a key role in TRAPS has led to a preference for IL-1 blockade as the optimal strategy to secure long-term control and minimize amyloidosis risk [
         <a href="#rid23">
          23,28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3143305163">
         <span class="h3">
          Patients at low risk for amyloidosis and mild symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with TRAPS who wish to try prophylactic therapy but lack a pathogenic or likely pathogenic variant and who have symptoms that are unpleasant but tolerable, we suggest a trial of
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         , at a dose of 0.6 mg orally once to twice daily, before initiating cytokine blockade  (
         <a class="graphic graphic_algorithm graphicRef142866" href="/z/d/graphic/142866.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
         Several series have explored the utility of
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         for TRAPS, largely in patients with R92Q and other low-penetrance variants [
         <a href="#rid56">
          56,57
         </a>
         ]. In one retrospective series of 24 patients, colchicine therapy resulted in a complete response in 3 (13 percent), partial response in 14 (58 percent), and no response in 7 (29 percent) [
         <a href="#rid56">
          56
         </a>
         ]. Stratifying by
         <em>
          TNFRSF1A
         </em>
         mutations, a response to colchicine was observed in only 2 of 19 patients (11 percent) bearing pathogenic or likely pathogenic variants but in 40 of 40 patients (100 percent) bearing either variants of uncertain significance or unclassified variants who also failed to meet Eurofever criteria for TRAPS [
         <a href="#rid9">
          9
         </a>
         ]. No published information is available with respect to the impact of colchicine on amyloidosis risk.
        </p>
        <p class="headingAnchor" id="H3738726076">
         <span class="h2">
          Referral
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with persistent symptoms or those who develop amyloidosis despite biologic therapy should be referred to regional or national centers specializing in the investigation and care of this rare disease.
        </p>
        <p class="headingAnchor" id="H2511405759">
         <span class="h2">
          Monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with TRAPS should receive routine monitoring, including assessment of inflammatory markers (erythrocyte sedimentation rate [ESR] and CRP and, if available, serum amyloid A and S100 proteins) to assess extent of disease control and urinalysis to screen for proteinuria, which is the typical presenting feature of amyloidosis [
         <a href="#rid28">
          28
         </a>
         ]. We perform such screening every 6 to 12 months, using quantitative measurement of spot urine protein and creatinine to screen for microalbuminuria, which is typically the earliest evidence of amyloidosis. Persistent elevation of inflammatory markers, in particular in the context of incipient amyloidosis, would be an indication for intensifying biologic therapy and/or referral to a center with specific TRAPS expertise.
        </p>
        <p class="headingAnchor" id="H2104146272">
         <span class="h2">
          Diagnosis of amyloidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Amyloidosis is usually identified on urinalysis screening, with the diagnosis confirmed by biopsy of kidney or intestine (see
         <a class="local">
          'Monitoring'
         </a>
         above). The duration between onset of TRAPS symptoms and diagnosis of amyloidosis has ranged from 3 to 71 years, with a median delay of 30 years [
         <a href="#rid27">
          27,29
         </a>
         ]. However, amyloidosis can be diagnosed prior to TRAPS (see
         <a class="local">
          'Secondary (AA) amyloidosis'
         </a>
         above). The diagnosis of amyloidosis is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1487818532">
         <span class="h2">
          Treatment of amyloidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with TRAPS who develop amyloidosis, we suggest treatment with IL-1 antagonists (
         <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">
          canakinumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">
          anakinra
         </a>
         ) over anti-TNF therapy (
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         ). We treat to a level sufficient to fully normalize inflammatory markers. There are no randomized trial data. Some uncontrolled case series of patients with TRAPS have demonstrated reversal or slowing of progression of amyloidosis with treatment with etanercept [
         <a href="#rid58">
          58-60
         </a>
         ], whereas others have shown good response to anakinra but only partial or transient response to etanercept [
         <a href="#rid27">
          27,29
         </a>
         ]. There are no published data for canakinumab for AA amyloidosis in TRAPS, but use is supported by indirect evidence in treating other periodic fever syndromes such as familial Mediterranean fever (FMF) [
         <a href="#rid61">
          61,62
         </a>
         ]. In addition, many patients prefer canakinumab over anakinra due to monthly rather than daily dosing. Treatment of AA amyloidosis is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5588.html" rel="external">
          "Treatment of AA (secondary) amyloidosis", section on 'Anticytokine therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4101505238">
         <span class="h2">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uncontrolled TRAPS has been associated with recurrent miscarriage, whereas successful pregnancy has been reported in TRAPS patients receiving IL-1 blockade [
         <a href="#rid9">
          9
         </a>
         ]. While safety data regarding IL-1 blockade in pregnancy remain limited, requiring discussion of potential risks and benefits with each patient, continued IL-1 blockade during conception and pregnancy is recommended, typically with
         <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">
          anakinra
         </a>
         given its longer track record of use in pregnancy.
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetics
         </strong>
         – Tumor necrosis factor (TNF) receptor-1 associated periodic syndrome (TRAPS) is a rare, autosomal dominant autoinflammatory syndrome resulting from pathogenic variants in the tumor necrosis factor receptor 1 (TNFR1) gene (TNF receptor superfamily member 1A [
         <em>
          TNFRSF1A
         </em>
         ]). (See
         <a class="local">
          'Genetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – Attacks typically occur every five to six weeks. Clinical hallmarks include protracted febrile periods (at least six days, though typically longer), myalgias, periorbital edema, migratory rash, and abdominal pain. Elevated inflammatory markers (erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]) are noted during and between episodes. Persistent inflammation may result in secondary amyloidosis. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of TRAPS is suggested by a history of recurrent fever and one or more of the other clinical features noted above, as well as absence of an underlying infection, autoimmune disease, or neoplastic disorder  (
         <a class="graphic graphic_table graphicRef101819" href="/z/d/graphic/101819.html" rel="external">
          table 1
         </a>
         ). The diagnosis is confirmed by genetic testing for common variants in the TNFR1 gene. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis includes all other causes of recurrent fevers, systemic lupus erythematosus (SLE), systemic juvenile idiopathic arthritis/adult-onset Still's disease, inflammatory bowel disease, vasculitis, and other autoinflammatory diseases. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Goals of treatment
         </strong>
         – The goals of treatment of TRAPS are to control symptoms, prevent recurrent attacks, and reduce the risk of amyloidosis by suppressing systemic inflammation, particularly in patients bearing pathogenic or likely pathogenic cysteine variants.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          On-demand treatment of acute attacks:
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mild attacks
         </strong>
         – For patients with mild attacks (low-grade fever and mild discomfort easily tolerable by the patient), we suggest treatment with a nonsteroidal antiinflammatory drug (NSAID) alone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). If symptoms increase, an oral glucocorticoid can be added as is done for typical attacks. (See
         <a class="local">
          'Mild attacks'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Typical attacks
         </strong>
         – For patients with typical attacks (eg, fever, myalgia, migratory rash, periorbital edema, and/or abdominal pain), we suggest treatment with an oral glucocorticoid (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The usual regimen is
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         or
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         1 mg/kg daily, maximum dose 60 mg/day, started at the onset of an attack followed by a gradual taper and discontinuation after 7 to 10 days. An alternative is treatment with
         <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">
          anakinra
         </a>
         , a recombinant interleukin (IL) 1 receptor antagonist, beginning at 100 mg daily and escalating to 200 mg daily if needed. (See
         <a class="local">
          'Typical attacks'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prophylactic therapy
         </strong>
         – On-demand treatment alone may be sufficient for the occasional patient with rare or mild flares and normal inflammatory markers between episodes. However, most patients with TRAPS have frequent attacks and/or ongoing inflammation even between attacks. Antiinflammatory agents (eg,
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         ) and/or cytokine blocking agents (eg, IL-1 antagonists [eg,
         <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">
          canakinumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">
          anakinra
         </a>
         ] and TNF inhibitors [eg,
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         ]) are used in these patients to control the disease and reduce the risk of glucocorticoid toxicity. The choice of therapy depends on the patient's
         <em>
          TNFRSF1A
         </em>
         mutation status, severity and frequency of attacks, and whether there is evidence of amyloidosis. Our suggested approach is as follows  (
         <a class="graphic graphic_algorithm graphicRef142866" href="/z/d/graphic/142866.html" rel="external">
          algorithm 1
         </a>
         ) (see
         <a class="local">
          'Management'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Lower-risk patients
         </strong>
         – For patients with TRAPS who lack a pathogenic or likely pathogenic
         <em>
          TNFRSF1A
         </em>
         variant and who have symptoms that are unpleasant but tolerable, we suggest treatment with
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         rather than on-demand treatment alone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Patients at low risk for amyloidosis and mild symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Higher-risk patients
         </strong>
         – This category includes patients with
         <strong>
          any
         </strong>
         of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Pathogenic or likely pathogenic
         <em>
          TNFRSF1A
         </em>
         variant
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Frequent attacks (more than three attacks per year)
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Inadequate response to oral glucocorticoids
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Persistent elevation of inflammatory markers between flares
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Evidence of AA amyloidosis
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients with any of these findings, we suggest treatment with
         <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">
          canakinumab
         </a>
         rather than other agents or on-demand treatment alone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For patients who do not respond to or do not tolerate canakinumab,
         <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">
          anakinra
         </a>
         is an acceptable alternative. For patients who do not respond to either IL-1 antagonist (canakinumab or anakinra),
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         is a third-line option. (See
         <a class="local">
          'Frequent or poorly controlled symptoms and/or risk factors for amyloidosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Partial response
         </strong>
         – For patients with pathogenic or likely pathogenic
         <em>
          TNFRSF1A
         </em>
         variants who exhibit an incomplete response to cytokine blockade (eg,
         <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">
          canakinumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">
          anakinra
         </a>
         , or
         <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">
          etanercept
         </a>
         ), we suggest adding
         <a class="drug drug_general" data-topicid="9293" href="/z/d/drug information/9293.html" rel="external">
          colchicine
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with AA amyloidosis
         </strong>
         – For patients with TRAPS who develop amyloidosis, the mainstay of treatment is to achieve control of the disease with IL-1 antagonists (
         <a class="drug drug_general" data-topicid="8906" href="/z/d/drug information/8906.html" rel="external">
          canakinumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">
          anakinra
         </a>
         ), as outlined in the previous bullets  (
         <a class="graphic graphic_algorithm graphicRef142866" href="/z/d/graphic/142866.html" rel="external">
          algorithm 1
         </a>
         ). The target of treatment is to fully normalize inflammatory markers. (See
         <a class="local">
          'Treatment of amyloidosis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5588.html" rel="external">
          "Treatment of AA (secondary) amyloidosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2831625634">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges E Richard Stiehm, MD, who contributed as a Section Editor to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Nigrovic PA, Lee PY, Hoffman HM. Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach. J Allergy Clin Immunol 2020; 146:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hull KM, Drewe E, Aksentijevich I, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002; 81:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lachmann HJ, Papa R, Gerhold K, et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis 2014; 73:2160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cantarini L, Rigante D, Merlini G, et al. The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up. Semin Arthritis Rheum 2014; 43:818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruiz-Ortiz E, Iglesias E, Soriano A, et al. Disease Phenotype and Outcome Depending on the Age at Disease Onset in Patients Carrying the R92Q Low-Penetrance Variant in TNFRSF1A Gene. Front Immunol 2017; 8:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ravet N, Rouaghe S, Dodé C, et al. Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis 2006; 65:1158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ueda N, Ida H, Washio M, et al. Clinical and Genetic Features of Patients With TNFRSF1A Variants in Japan: Findings of a Nationwide Survey. Arthritis Rheumatol 2016; 68:2760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papa R, Lane T, Minden K, et al. INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry. J Allergy Clin Immunol Pract 2021; 9:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Jesus AA, Canna SW, Liu Y, Goldbach-Mansky R. Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling. Annu Rev Immunol 2015; 33:823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nedjai B, Hitman GA, Yousaf N, et al. Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008; 58:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Osualdo A, Ferlito F, Prigione I, et al. Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications. Arthritis Rheum 2006; 54:998.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siebert S, Amos N, Fielding CA, et al. Reduced tumor necrosis factor signaling in primary human fibroblasts containing a tumor necrosis factor receptor superfamily 1A mutant. Arthritis Rheum 2005; 52:1287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bulua AC, Simon A, Maddipati R, et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 2011; 208:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rebelo SL, Amel-Kashipaz MR, Radford PM, et al. Novel markers of inflammation identified in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) by transcriptomic analysis of effects of TRAPS-associated tumor necrosis factor receptor type I mutations in an endothelial cell line. Arthritis Rheum 2009; 60:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lobito AA, Kimberley FC, Muppidi JR, et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 2006; 108:1320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simon A, Park H, Maddipati R, et al. Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc Natl Acad Sci U S A 2010; 107:9801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bachetti T, Chiesa S, Castagnola P, et al. Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS). Ann Rheum Dis 2013; 72:1044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Benedetti F, Gattorno M, Anton J, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med 2018; 378:1908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dodé C, André M, Bienvenu T, et al. The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2002; 46:2181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmaltz R, Vogt T, Reichrath J. Skin manifestations in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Dermatoendocrinol 2010; 2:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cantarini L, Lucherini OM, Brucato A, et al. Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clin Res Cardiol 2012; 101:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano M, Arici ZS, Piskin D, et al. The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Ann Rheum Dis 2022; 81:907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aksentijevich I, Galon J, Soares M, et al. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 2001; 69:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kallinich T, Haffner D, Rudolph B, et al. "Periodic fever" without fever: two cases of non-febrile TRAPS with mutations in the TNFRSF1A gene presenting with episodes of inflammation or monosymptomatic amyloidosis. Ann Rheum Dis 2006; 65:958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005; 5:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lane T, Loeffler JM, Rowczenio DM, et al. AA amyloidosis complicating the hereditary periodic fever syndromes. Arthritis Rheum 2013; 65:1116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis 2015; 74:1636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delaleu J, Deshayes S, Rodrigues F, et al. Tumour necrosis factor receptor-1 associated periodic syndrome (TRAPS)-related AA amyloidosis: a national case series and systematic review. Rheumatology (Oxford) 2021; 60:5775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gattorno M, Hofer M, Federici S, et al. Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis 2019; 78:1025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaggiano C, Rigante D, Hernández-Rodríguez J, et al. Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network. Ther Adv Musculoskelet Dis 2021; 13:1759720X211037178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rowczenio DM, Trojer H, Omoyinmi E, et al. Brief Report: Association of Tumor Necrosis Factor Receptor-Associated Periodic Syndrome With Gonosomal Mosaicism of a Novel 24-Nucleotide TNFRSF1A Deletion. Arthritis Rheumatol 2016; 68:2044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Assrawi E, Louvrier C, El Khouri E, et al. Mosaic variants in TNFRSF1A: an emerging cause of tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 2022; 62:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manthiram K, Zhou Q, Aksentijevich I, Kastner DL. The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nat Immunol 2017; 18:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gattorno M, Sormani MP, D'Osualdo A, et al. A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum 2008; 58:1823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodero MP, Crow YJ. Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview. J Exp Med 2016; 213:2527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee-Kirsch MA. The Type I Interferonopathies. Annu Rev Med 2017; 68:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rice GI, Melki I, Frémond ML, et al. Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease. J Clin Immunol 2017; 37:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shinar Y, Obici L, Aksentijevich I, et al. Guidelines for the genetic diagnosis of hereditary recurrent fevers. Ann Rheum Dis 2012; 71:1599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ter Haar N, Lachmann H, Özen S, et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2013; 72:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grimwood C, Despert V, Jeru I, Hentgen V. On-demand treatment with anakinra: a treatment option for selected TRAPS patients. Rheumatology (Oxford) 2015; 54:1749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gattorno M, Obici L, Cattalini M, et al. Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Ann Rheum Dis 2017; 76:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gattorno M, Obici L, Penadés IC, et al. Long-Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor-Associated Periodic Syndrome: Results From a Phase III Trial. Arthritis Rheumatol 2023.
          </a>
         </li>
         <li class="breakAll">
          FDA approves expanded indications for canakinumab. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm522283.htm.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winthrop KL, Mariette X, Silva JT, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 2018; 24 Suppl 2:S21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simon A, Bodar EJ, van der Hilst JC, et al. Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med 2004; 117:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sacré K, Brihaye B, Lidove O, et al. Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy. J Rheumatol 2008; 35:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gattorno M, Pelagatti MA, Meini A, et al. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2008; 58:1516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drewe E, McDermott EM, Powell PT, et al. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology (Oxford) 2003; 42:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bulua AC, Mogul DB, Aksentijevich I, et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum 2012; 64:908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stojanov S, Dejaco C, Lohse P, et al. Clinical and functional characterisation of a novel TNFRSF1A c.605T&gt;A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. Ann Rheum Dis 2008; 67:1292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nedjai B, Hitman GA, Quillinan N, et al. Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2009; 60:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vaitla PM, Radford PM, Tighe PJ, et al. Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum 2011; 63:1151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akasbi N, Soyfoo MS. Successful treatment of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) with tocilizumab: A case report. Eur J Rheumatol 2015; 2:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           La Torre F, Muratore M, Vitale A, et al. Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Rheumatol Int 2015; 35:1943.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vitale A, Sota J, Obici L, et al. Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network. Mediators Inflamm 2020; 2020:1936960.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pelagatti MA, Meini A, Caorsi R, et al. Long-term clinical profile of children with the low-penetrance R92Q mutation of the TNFRSF1A gene. Arthritis Rheum 2011; 63:1141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 2005; 17:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drewe E, Huggins ML, Morgan AG, et al. Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 2004; 43:1405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kallinich T, Briese S, Roesler J, et al. Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis. J Rheumatol 2004; 31:2519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Varan Ö, Kucuk H, Babaoglu H, et al. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Mod Rheumatol 2019; 29:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trabulus S, Korkmaz M, Kaya E, Seyahi N. Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever. Clin Transplant 2018; 32:e13345.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5580 Version 19.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33160483" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10199409" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12352631" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23965844" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24393624" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28396659" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Disease Phenotype and Outcome Depending on the Age at Disease Onset in Patients Carrying the R92Q Low-Penetrance Variant in TNFRSF1A Gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16569687" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27332769" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Clinical and Genetic Features of Patients With TNFRSF1A Variants in Japan: Findings of a Nationwide Survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33181346" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25706096" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18163488" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16508982" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15818692" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Reduced tumor necrosis factor signaling in primary human fibroblasts containing a tumor necrosis factor receptor superfamily 1A mutant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21282379" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19116900" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Novel markers of inflammation identified in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) by transcriptomic analysis of effects of TRAPS-associated tumor necrosis factor receptor type I mutations in an endothelial cell line.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16684962" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20457915" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23117241" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29768139" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12209523" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21547145" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Skin manifestations in tumor necrosis factor receptor-associated periodic syndrome (TRAPS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22311714" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35623638" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11443543" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16308343" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : "Periodic fever" without fever: two cases of non-febrile TRAPS with mutations in the TNFRSF1A gene presenting with episodes of inflammation or monosymptomatic amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16284730" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Hereditary periodic fever and reactive amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23280696" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : AA amyloidosis complicating the hereditary periodic fever syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26109736" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Recommendations for the management of autoinflammatory diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33715002" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Tumour necrosis factor receptor-1 associated periodic syndrome (TRAPS)-related AA amyloidosis: a national case series and systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31018962" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Classification criteria for autoinflammatory recurrent fevers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34527082" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26992170" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Brief Report: Association of Tumor Necrosis Factor Receptor-Associated Periodic Syndrome With Gonosomal Mosaicism of a Novel 24-Nucleotide TNFRSF1A Deletion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35640127" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Mosaic variants in TNFRSF1A: an emerging cause of tumour necrosis factor receptor-associated periodic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28722725" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18512793" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27821552" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27813875" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The Type I Interferonopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27943079" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22661645" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Guidelines for the genetic diagnosis of hereditary recurrent fevers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22753383" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26078218" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : On-demand treatment with anakinra: a treatment option for selected TRAPS patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27269295" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37668289" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Long-Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor-Associated Periodic Syndrome: Results From a Phase III Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37668289" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Long-Term Efficacy and Safety of Canakinumab in Patients With Tumor Necrosis Factor Receptor-Associated Periodic Syndrome: Results From a Phase III Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29447987" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15300976" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Beneficial response to interleukin 1 receptor antagonist in traps.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18260167" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18438813" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12595616" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22006113" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18180277" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Clinical and functional characterisation of a novel TNFRSF1A c.605T&gt;A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19180495" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21225679" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27708919" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Successful treatment of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) with tocilizumab: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26048626" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32565720" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21225694" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Long-term clinical profile of children with the low-penetrance R92Q mutation of the TNFRSF1A gene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16093838" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Familial autoinflammatory diseases: genetics, pathogenesis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15316120" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15570662" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29578360" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29981275" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
